Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 34793718

(177)Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2021 Dec
First author
Strosberg JR

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2021 Dec;22(12):1645-1646. doi: 10.1016/S1470-2045(21)00593-3.
    note
    Source null
    related pmid
    34793720
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2022 Feb;23(2):e59. doi: 10.1016/S1470-2045(22)00028-6.
    note
    Source null
    related pmid
    35114131
    relationship
    Erratum in

Authors and identifiers

  1. name
    Strosberg JR
    type
    Author
  2. name
    Caplin ME
    type
    Author
  3. name
    Kunz PL
    type
    Author
  4. name
    Ruszniewski PB
    type
    Author
  5. name
    Bodei L
    type
    Author
  6. name
    Hendifar A
    type
    Author
  7. name
    Mittra E
    type
    Author
  8. name
    Wolin EM
    type
    Author
  9. name
    Yao JC
    type
    Author
  10. name
    Pavel ME
    type
    Author
  11. name
    Grande E
    type
    Author
  12. name
    Van Cutsem E
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Strosberg JR
    type
    Author
  2. name
    Caplin ME
    type
    Author
  3. name
    Kunz PL
    type
    Author
  4. name
    Ruszniewski PB
    type
    Author
  5. name
    Bodei L
    type
    Author
  6. name
    Hendifar A
    type
    Author
  7. name
    Mittra E
    type
    Author
  8. name
    Wolin EM
    type
    Author
  9. name
    Yao JC
    type
    Author
  10. name
    Pavel ME
    type
    Author
  11. name
    Grande E
    type
    Author
  12. name
    Van Cutsem E
    type
    Author
bibliography ids
  1. nci-bib-bba506176f85a9188fee67c8
book metadata
content sha256
af9a2d2fd206dc2de6e68c919549e4f7c2a796eacca3faf5e7fbd0892daa69ef
document type
citation
dois
  1. 10.1016/S1470-2045(21)00572-6
electronic publication date
display
2021 Nov 15
precision
day
year
2021
evidence scope
bibliographic_metadata_only
id
pubmed:34793718
immutable id
pubmed:34793718@af9a2d2fd206dc2de6e68c919549e4f7c2a796eacca3faf5e7fbd0892daa69ef
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
12
name
The Lancet. Oncology
nlm unique id
100957246
pages
1752-1763
volume
22
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2021 Dec;22(12):1645-1646. doi: 10.1016/S1470-2045(21)00593-3.
    note
    Source null
    related pmid
    34793720
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2022 Feb;23(2):e59. doi: 10.1016/S1470-2045(22)00028-6.
    note
    Source null
    related pmid
    35114131
    relationship
    Erratum in
outcomes validated
false
pmid
34793718
provenance
batch id
3f4d1914d2afe41e9e70
provider
NCBI PubMed ESummary
record sha256
aee9092aaf5198c621ffa1dce630b19aa8592fa2fee3643ccfd3141841e8e459
response sha256
0ceeb248a527e54c6f72dd28d20f7abec08a973fe2e10de00bede4895add09e7
retrieved at
2026-09-09T23:48:06.522634+00:00
publication date
display
2021 Dec
precision
month
year
2021
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/34793718/
title
(177)Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial.

Preserved source evidence · Not medical advice